Clinical Trial Update: A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. [Phase 3]

View source ↗

Summary

A completed Phase 3 rollover study evaluating the safety and efficacy of palovarotene capsules in participants with fibrodysplasia ossificans progressiva (FOP),…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Palovarotene (palovarotene)

Snippet

Sponsor: Ipsen | Conditions: Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 | Status: COMPLETED | Results posted: 2025-06-13